Product Review

Cyltezo

Boehringer Ingelheim Pharmaceuticals, Inc, announces US Food and Drug Administration approval of the biosimilar Cyltezo (adalimumab-adbm) in a prefilled syringe for the treatment of plaque psoriasis and psoriatic arthritis as well as other chronic inflammatory diseases. Cyltezo is not commercially available at this time. For more information, visit www.boehringer-ingelheim.us.

Facing Forward App

Cutanea Life Sciences, Inc, introduces Facing Forward, a mobile app for patients with acne to track their treatment with Aktipak (erythromycin and benzoyl peroxide) Gel 3%/5%. The app features a camera function for users to take photographs to track their progress, dosing reminders, prescription refill reminders, acne information resources, and a compliance report so that the physician can determine if the patient is using the medication properly. This app is available free through the App Store or Google Play. For more information, visit www.cutanea.com.

Glytone Dark Spot Corrector

Pierre Fabre Dermo Cosmetique USA introduces the Glytone Dark Spot Corrector, a brightening formula with hydroquinone 2% to help reduce the appearance of pigmentation changes due to pregnancy, use of oral contraceptives, skin aging, or photodamage. It also contains glycolic acid to exfoliate dead cells from the skin’s surface and kojic acid to brighten the skin. For more information, visit www.glytone-usa.com.

Loyon

IntraDerm Pharmaceuticals, a division of Sonoma Pharmaceuticals, Inc, announces US commercialization of Loyon to manage and relieve the scaling, erythema, and pruritus associated with various types of dermatoses including seborrhea and seborrheic dermatitis. Loyon is a combination of the dry emollient Cetiol CC and the medical silicone oil dimethicone. It is a fast and effective treatment for scaling associated with seborrheic dermatitis or psoriasis, which impacts patient quality of life. This product received 510(k) clearance from the US Food and Drug Administration in March 2017. For more information, visit www.intraderm.com.

Stelara

Janssen Biotech, Inc, announces US Food and Drug Administration approval of Stelara (ustekinumab) for the treatment of moderate to severe plaque psoriasis in adolescents (≥12 years of age) who are candidates for phototherapy or systemic therapy. Stelara was first approved for the treatment of plaque psoriasis in adults in 2009. For more information, visit www.stelarahcp.com.


If you would like your product included in Product News, please email a press release to the Editorial Office at cutis@frontlinemedcom.com.

Cyltezo

Boehringer Ingelheim Pharmaceuticals, Inc, announces US Food and Drug Administration approval of the biosimilar Cyltezo (adalimumab-adbm) in a prefilled syringe for the treatment of plaque psoriasis and psoriatic arthritis as well as other chronic inflammatory diseases. Cyltezo is not commercially available at this time. For more information, visit www.boehringer-ingelheim.us.

Facing Forward App

Cutanea Life Sciences, Inc, introduces Facing Forward, a mobile app for patients with acne to track their treatment with Aktipak (erythromycin and benzoyl peroxide) Gel 3%/5%. The app features a camera function for users to take photographs to track their progress, dosing reminders, prescription refill reminders, acne information resources, and a compliance report so that the physician can determine if the patient is using the medication properly. This app is available free through the App Store or Google Play. For more information, visit www.cutanea.com.

Glytone Dark Spot Corrector

Pierre Fabre Dermo Cosmetique USA introduces the Glytone Dark Spot Corrector, a brightening formula with hydroquinone 2% to help reduce the appearance of pigmentation changes due to pregnancy, use of oral contraceptives, skin aging, or photodamage. It also contains glycolic acid to exfoliate dead cells from the skin’s surface and kojic acid to brighten the skin. For more information, visit www.glytone-usa.com.

Loyon

IntraDerm Pharmaceuticals, a division of Sonoma Pharmaceuticals, Inc, announces US commercialization of Loyon to manage and relieve the scaling, erythema, and pruritus associated with various types of dermatoses including seborrhea and seborrheic dermatitis. Loyon is a combination of the dry emollient Cetiol CC and the medical silicone oil dimethicone. It is a fast and effective treatment for scaling associated with seborrheic dermatitis or psoriasis, which impacts patient quality of life. This product received 510(k) clearance from the US Food and Drug Administration in March 2017. For more information, visit www.intraderm.com.

Stelara

Janssen Biotech, Inc, announces US Food and Drug Administration approval of Stelara (ustekinumab) for the treatment of moderate to severe plaque psoriasis in adolescents (≥12 years of age) who are candidates for phototherapy or systemic therapy. Stelara was first approved for the treatment of plaque psoriasis in adults in 2009. For more information, visit www.stelarahcp.com.


If you would like your product included in Product News, please email a press release to the Editorial Office at cutis@frontlinemedcom.com.

Cyltezo

Boehringer Ingelheim Pharmaceuticals, Inc, announces US Food and Drug Administration approval of the biosimilar Cyltezo (adalimumab-adbm) in a prefilled syringe for the treatment of plaque psoriasis and psoriatic arthritis as well as other chronic inflammatory diseases. Cyltezo is not commercially available at this time. For more information, visit www.boehringer-ingelheim.us.

Facing Forward App

Cutanea Life Sciences, Inc, introduces Facing Forward, a mobile app for patients with acne to track their treatment with Aktipak (erythromycin and benzoyl peroxide) Gel 3%/5%. The app features a camera function for users to take photographs to track their progress, dosing reminders, prescription refill reminders, acne information resources, and a compliance report so that the physician can determine if the patient is using the medication properly. This app is available free through the App Store or Google Play. For more information, visit www.cutanea.com.

Glytone Dark Spot Corrector

Pierre Fabre Dermo Cosmetique USA introduces the Glytone Dark Spot Corrector, a brightening formula with hydroquinone 2% to help reduce the appearance of pigmentation changes due to pregnancy, use of oral contraceptives, skin aging, or photodamage. It also contains glycolic acid to exfoliate dead cells from the skin’s surface and kojic acid to brighten the skin. For more information, visit www.glytone-usa.com.

Loyon

IntraDerm Pharmaceuticals, a division of Sonoma Pharmaceuticals, Inc, announces US commercialization of Loyon to manage and relieve the scaling, erythema, and pruritus associated with various types of dermatoses including seborrhea and seborrheic dermatitis. Loyon is a combination of the dry emollient Cetiol CC and the medical silicone oil dimethicone. It is a fast and effective treatment for scaling associated with seborrheic dermatitis or psoriasis, which impacts patient quality of life. This product received 510(k) clearance from the US Food and Drug Administration in March 2017. For more information, visit www.intraderm.com.

Stelara

Janssen Biotech, Inc, announces US Food and Drug Administration approval of Stelara (ustekinumab) for the treatment of moderate to severe plaque psoriasis in adolescents (≥12 years of age) who are candidates for phototherapy or systemic therapy. Stelara was first approved for the treatment of plaque psoriasis in adults in 2009. For more information, visit www.stelarahcp.com.


If you would like your product included in Product News, please email a press release to the Editorial Office at cutis@frontlinemedcom.com.

NIPT SCREENING FOR TWIN ZYGOSITY AND GENETIC RISK FACTORS

Building on its history as the only NIPT that can differentiate between the mother’s and the baby’s DNA, Panorama is now also the only NIPT to distinguish between each twin’s DNA, says Natera. Panorama’s unique technology enables it to determine zygosity and each twin’s gender while also allowing it to identify risk for more genetic conditions in twin pregnancies than other NIPTs, including monosomy X, sex chromosome trisomies, and 22q11.2 deletion syndrome.

FOR MORE INFORMATION, VISIT: http://www.panoramatest.com/panorama-test/

NEW DRUG FOR TREATING BACTERIAL VAGINOSIS

Symbiomix Therapeutics reported that FDA approval was supported by comprehensive studies that found the single-dose secnidazole 2g was efficacious. All treatment-emergent adverse effects were mild or moderate in intensity; no serious adverse events were reported. Solosec will be available to patients in the first quarter of 2018.

FOR MORE INFORMATION, VISIT: https://symbiomix.com/sym-1219/

Share your thoughts! Send your Letter to the Editor to rbarbieri@frontlinemedcom.com. Please include your name and the city and state in which you practice.

NIPT SCREENING FOR TWIN ZYGOSITY AND GENETIC RISK FACTORS

Building on its history as the only NIPT that can differentiate between the mother’s and the baby’s DNA, Panorama is now also the only NIPT to distinguish between each twin’s DNA, says Natera. Panorama’s unique technology enables it to determine zygosity and each twin’s gender while also allowing it to identify risk for more genetic conditions in twin pregnancies than other NIPTs, including monosomy X, sex chromosome trisomies, and 22q11.2 deletion syndrome.

FOR MORE INFORMATION, VISIT: http://www.panoramatest.com/panorama-test/

NEW DRUG FOR TREATING BACTERIAL VAGINOSIS

Symbiomix Therapeutics reported that FDA approval was supported by comprehensive studies that found the single-dose secnidazole 2g was efficacious. All treatment-emergent adverse effects were mild or moderate in intensity; no serious adverse events were reported. Solosec will be available to patients in the first quarter of 2018.

FOR MORE INFORMATION, VISIT: https://symbiomix.com/sym-1219/

Share your thoughts! Send your Letter to the Editor to rbarbieri@frontlinemedcom.com. Please include your name and the city and state in which you practice.

NIPT SCREENING FOR TWIN ZYGOSITY AND GENETIC RISK FACTORS

Building on its history as the only NIPT that can differentiate between the mother’s and the baby’s DNA, Panorama is now also the only NIPT to distinguish between each twin’s DNA, says Natera. Panorama’s unique technology enables it to determine zygosity and each twin’s gender while also allowing it to identify risk for more genetic conditions in twin pregnancies than other NIPTs, including monosomy X, sex chromosome trisomies, and 22q11.2 deletion syndrome.

FOR MORE INFORMATION, VISIT: http://www.panoramatest.com/panorama-test/

NEW DRUG FOR TREATING BACTERIAL VAGINOSIS

Symbiomix Therapeutics reported that FDA approval was supported by comprehensive studies that found the single-dose secnidazole 2g was efficacious. All treatment-emergent adverse effects were mild or moderate in intensity; no serious adverse events were reported. Solosec will be available to patients in the first quarter of 2018.

FOR MORE INFORMATION, VISIT: https://symbiomix.com/sym-1219/

Share your thoughts! Send your Letter to the Editor to rbarbieri@frontlinemedcom.com. Please include your name and the city and state in which you practice.

COLPOSCOPY BRUSHES SHOW BETTER TISSUE YIELD

A new study from the University of California–Riverside and Aurora Diagnostics in Palm Beach, Florida, evaluated 10,000 colposcopy workups and found that the disposable Histologics Soft-ECC and SoftBiopsy curettes were superior in tissue yield and offered a lower risk of cross contamination than metal curettes.

The Soft-ECC Endocervical Curette Tissue Collection System is used to biopsy the endocervical canal during colposcopy or evaluation for abnormal uterine bleeding. It gently frictionally abrades and collects transepithelial tissue samples into the Kylon fabric. The Soft-ECC-S has a smaller pad for the short, shallow, or stenotic cervix.

During exocervical biopsy with the SoftBiopsy Gynecological Biopsy Device, the Kylon fabric hooks rake across the tissue plane dislodging and shearing tissue strips and fragments from just below the basement membrane to collect in the fabric.

Both products have tips that are snapped off at the scored handle and placed in a fixative vial for transport to the laboratory.

FOR MORE INFORMATION, VISIT: https://www.histologics.com/

NONINVASIVE BODY CONTOURING

The Cynosure division of Hologic has just received US Food and Drug Administration (FDA) expanded clearance for SculpSure for noninvasive body contouring (lipolysis) of back, inner, and outer thighs. SculpSure is clinically proven to permanently eliminate fat cells and is already FDA-cleared to treat the abdomen and love handles (flanks).

According to Hologic, SculpSure uses a selective wavelength laser that precisely targets fat cells under the skin without affecting the skin’s surface. The laser raises the temperature of body fat to disrupt and destroy these cells, which are naturally eliminated over time and do not return or regenerate. Hologic says that patients are able to achieve desired results, without downtime or surgery, through customized treatment plans, each lasting only 25 minutes. Results can be seen as quickly as 6 weeks; optimal results typically are seen at 12 weeks, they say.

FOR MORE INFORMATION, VISIT: http://www.sculpsure.com

SOFTWARE PLATFORM FOR OBGYNS

drchrono offers software platforms for medical offices, including electronic health records (EHR), practice management, medical billing, revenue cycle management (RCM), and health care application programming interface (API) tools for iPad, iPhone, and web. Products are available for small and large practice groups, urgent care centers, and specialties, including ObGyns. A patient can complete forms and schedule visits through the Patient Portal as well as receive educational materials through HIPAA-compliant messaging and face-to-face telemedicine.

drchrono says its cloud-based platform allows ObGyns to chart in seconds using customizable medical forms, medical speech-to-text, and photo/drawing tools. ObGyn-specific ICD10, Current Procedural Terminology, and E&M codes can autopopulate into forms. Prenatal flow sheets and other clinical forms can be sent to L&D, other providers, or billing departments using drchrono’s direct messaging integration with the local hospital EHR or e-Fax. Prenatal and blood testing, ultrasounds, paper charts, and photographs can be ordered, tracked, and shared with patients and providers.

FOR MORE INFORMATION, VISIT: https://www.drchrono.com/

MAGNETIC DILATOR THERAPY FOR DYSPAREUNIA

The VuVa Magnetic Dilator Therapy is a nonsurgical, nonprescription program that VuVatech announces has been proven to relieve pelvic pain and dyspareunia caused by vaginismus, vulvodynia, and vaginal atrophy.

The VuVa Vaginal Dilator Set contains more than 60 neodymium magnets. With iron a component of blood that carries oxygen, when the magnet is placed next to a painful area, it draws fresh oxygenated blood to the nerves and surrounding muscles for increased blood circulation that accelerates healing while reducing pain. When a VuVa Magnetic Vaginal Dilator is used 20 minutes before intercourse, soft tissue lengthens, relaxing and calming muscles, ligaments, and nerves.

A nonmagnetic full dilator set is available for women who are trying to get pregnant and for women with pacemakers or defibrillators.

This product is not FDA approved, is not sold as a medical device, and is not intended to diagnose, treat, cure, or prevent any disease. Effectiveness varies, according to the manufacturer.

FOR MORE INFORMATION, VISIT: https://www.vuvatech.com/

Share your thoughts! Send your Letter to the Editor to rbarbieri@frontlinemedcom.com. Please include your name and the city and state in which you practice.

COLPOSCOPY BRUSHES SHOW BETTER TISSUE YIELD

A new study from the University of California–Riverside and Aurora Diagnostics in Palm Beach, Florida, evaluated 10,000 colposcopy workups and found that the disposable Histologics Soft-ECC and SoftBiopsy curettes were superior in tissue yield and offered a lower risk of cross contamination than metal curettes.

The Soft-ECC Endocervical Curette Tissue Collection System is used to biopsy the endocervical canal during colposcopy or evaluation for abnormal uterine bleeding. It gently frictionally abrades and collects transepithelial tissue samples into the Kylon fabric. The Soft-ECC-S has a smaller pad for the short, shallow, or stenotic cervix.

During exocervical biopsy with the SoftBiopsy Gynecological Biopsy Device, the Kylon fabric hooks rake across the tissue plane dislodging and shearing tissue strips and fragments from just below the basement membrane to collect in the fabric.

Both products have tips that are snapped off at the scored handle and placed in a fixative vial for transport to the laboratory.

FOR MORE INFORMATION, VISIT: https://www.histologics.com/

NONINVASIVE BODY CONTOURING

The Cynosure division of Hologic has just received US Food and Drug Administration (FDA) expanded clearance for SculpSure for noninvasive body contouring (lipolysis) of back, inner, and outer thighs. SculpSure is clinically proven to permanently eliminate fat cells and is already FDA-cleared to treat the abdomen and love handles (flanks).

According to Hologic, SculpSure uses a selective wavelength laser that precisely targets fat cells under the skin without affecting the skin’s surface. The laser raises the temperature of body fat to disrupt and destroy these cells, which are naturally eliminated over time and do not return or regenerate. Hologic says that patients are able to achieve desired results, without downtime or surgery, through customized treatment plans, each lasting only 25 minutes. Results can be seen as quickly as 6 weeks; optimal results typically are seen at 12 weeks, they say.

FOR MORE INFORMATION, VISIT: http://www.sculpsure.com

SOFTWARE PLATFORM FOR OBGYNS

drchrono offers software platforms for medical offices, including electronic health records (EHR), practice management, medical billing, revenue cycle management (RCM), and health care application programming interface (API) tools for iPad, iPhone, and web. Products are available for small and large practice groups, urgent care centers, and specialties, including ObGyns. A patient can complete forms and schedule visits through the Patient Portal as well as receive educational materials through HIPAA-compliant messaging and face-to-face telemedicine.

drchrono says its cloud-based platform allows ObGyns to chart in seconds using customizable medical forms, medical speech-to-text, and photo/drawing tools. ObGyn-specific ICD10, Current Procedural Terminology, and E&M codes can autopopulate into forms. Prenatal flow sheets and other clinical forms can be sent to L&D, other providers, or billing departments using drchrono’s direct messaging integration with the local hospital EHR or e-Fax. Prenatal and blood testing, ultrasounds, paper charts, and photographs can be ordered, tracked, and shared with patients and providers.

FOR MORE INFORMATION, VISIT: https://www.drchrono.com/

MAGNETIC DILATOR THERAPY FOR DYSPAREUNIA

The VuVa Magnetic Dilator Therapy is a nonsurgical, nonprescription program that VuVatech announces has been proven to relieve pelvic pain and dyspareunia caused by vaginismus, vulvodynia, and vaginal atrophy.

The VuVa Vaginal Dilator Set contains more than 60 neodymium magnets. With iron a component of blood that carries oxygen, when the magnet is placed next to a painful area, it draws fresh oxygenated blood to the nerves and surrounding muscles for increased blood circulation that accelerates healing while reducing pain. When a VuVa Magnetic Vaginal Dilator is used 20 minutes before intercourse, soft tissue lengthens, relaxing and calming muscles, ligaments, and nerves.

A nonmagnetic full dilator set is available for women who are trying to get pregnant and for women with pacemakers or defibrillators.

This product is not FDA approved, is not sold as a medical device, and is not intended to diagnose, treat, cure, or prevent any disease. Effectiveness varies, according to the manufacturer.

FOR MORE INFORMATION, VISIT: https://www.vuvatech.com/

Share your thoughts! Send your Letter to the Editor to rbarbieri@frontlinemedcom.com. Please include your name and the city and state in which you practice.

COLPOSCOPY BRUSHES SHOW BETTER TISSUE YIELD

A new study from the University of California–Riverside and Aurora Diagnostics in Palm Beach, Florida, evaluated 10,000 colposcopy workups and found that the disposable Histologics Soft-ECC and SoftBiopsy curettes were superior in tissue yield and offered a lower risk of cross contamination than metal curettes.

The Soft-ECC Endocervical Curette Tissue Collection System is used to biopsy the endocervical canal during colposcopy or evaluation for abnormal uterine bleeding. It gently frictionally abrades and collects transepithelial tissue samples into the Kylon fabric. The Soft-ECC-S has a smaller pad for the short, shallow, or stenotic cervix.

During exocervical biopsy with the SoftBiopsy Gynecological Biopsy Device, the Kylon fabric hooks rake across the tissue plane dislodging and shearing tissue strips and fragments from just below the basement membrane to collect in the fabric.

Both products have tips that are snapped off at the scored handle and placed in a fixative vial for transport to the laboratory.

FOR MORE INFORMATION, VISIT: https://www.histologics.com/

NONINVASIVE BODY CONTOURING

The Cynosure division of Hologic has just received US Food and Drug Administration (FDA) expanded clearance for SculpSure for noninvasive body contouring (lipolysis) of back, inner, and outer thighs. SculpSure is clinically proven to permanently eliminate fat cells and is already FDA-cleared to treat the abdomen and love handles (flanks).

According to Hologic, SculpSure uses a selective wavelength laser that precisely targets fat cells under the skin without affecting the skin’s surface. The laser raises the temperature of body fat to disrupt and destroy these cells, which are naturally eliminated over time and do not return or regenerate. Hologic says that patients are able to achieve desired results, without downtime or surgery, through customized treatment plans, each lasting only 25 minutes. Results can be seen as quickly as 6 weeks; optimal results typically are seen at 12 weeks, they say.

FOR MORE INFORMATION, VISIT: http://www.sculpsure.com

SOFTWARE PLATFORM FOR OBGYNS

drchrono offers software platforms for medical offices, including electronic health records (EHR), practice management, medical billing, revenue cycle management (RCM), and health care application programming interface (API) tools for iPad, iPhone, and web. Products are available for small and large practice groups, urgent care centers, and specialties, including ObGyns. A patient can complete forms and schedule visits through the Patient Portal as well as receive educational materials through HIPAA-compliant messaging and face-to-face telemedicine.

drchrono says its cloud-based platform allows ObGyns to chart in seconds using customizable medical forms, medical speech-to-text, and photo/drawing tools. ObGyn-specific ICD10, Current Procedural Terminology, and E&M codes can autopopulate into forms. Prenatal flow sheets and other clinical forms can be sent to L&D, other providers, or billing departments using drchrono’s direct messaging integration with the local hospital EHR or e-Fax. Prenatal and blood testing, ultrasounds, paper charts, and photographs can be ordered, tracked, and shared with patients and providers.

FOR MORE INFORMATION, VISIT: https://www.drchrono.com/

MAGNETIC DILATOR THERAPY FOR DYSPAREUNIA

The VuVa Magnetic Dilator Therapy is a nonsurgical, nonprescription program that VuVatech announces has been proven to relieve pelvic pain and dyspareunia caused by vaginismus, vulvodynia, and vaginal atrophy.

The VuVa Vaginal Dilator Set contains more than 60 neodymium magnets. With iron a component of blood that carries oxygen, when the magnet is placed next to a painful area, it draws fresh oxygenated blood to the nerves and surrounding muscles for increased blood circulation that accelerates healing while reducing pain. When a VuVa Magnetic Vaginal Dilator is used 20 minutes before intercourse, soft tissue lengthens, relaxing and calming muscles, ligaments, and nerves.

A nonmagnetic full dilator set is available for women who are trying to get pregnant and for women with pacemakers or defibrillators.

This product is not FDA approved, is not sold as a medical device, and is not intended to diagnose, treat, cure, or prevent any disease. Effectiveness varies, according to the manufacturer.

FOR MORE INFORMATION, VISIT: https://www.vuvatech.com/

Share your thoughts! Send your Letter to the Editor to rbarbieri@frontlinemedcom.com. Please include your name and the city and state in which you practice.

Avène A-OXitive

Pierre Fabre Dermo-Cosmetique introduces Avène A-OXitive Antioxidant Defense Serum and Avène A-OXitive Antioxidant Water-Cream to fight against oxidative stress. Stable forms of time-released vitamin E and vitamin C work synergistically to defend against environmental aggressors without irritation. Both products contain hyaluronic acid to visibly plump and firm the skin and soothing Avène thermal spring water to soften and restore the skin’s balance. To preserve stability, each formula comes in an airless pump bottle. For more information, visit www.aveneusa.com.

Orencia

Bristol-Myers Squibb Company announces US Food and Drug Administration approval of Orencia (abatacept) for the treatment of adults with active psoriatic arthritis. Orencia is available in both intravenous and subcutaneous injection formulations. It should not be administered concomitantly with tumor necrosis factor antagonists and is not recommended for use with other biologic rheumatoid arthritis therapy. Orencia also is indicated for the treatment of adult rheumatoid arthritis and juvenile idiopathic arthritis. For more information, visit www.orenciahcp.com.

Tremfya

Janssen Biotech, Inc, announces US Food and Drug Administration approval of Tremfya (guselkumab) for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Tremfya is a biologic therapy that selectively blocks only IL-23, a cytokine that plays a key role in plaque psoriasis. Tremfya is administered as a 100-mg subcutaneous injection every 8 weeks, following 2 starter doses at weeks 0 and 4. Clinical studies documented skin clearance at week 16 and up to week 48. For more information, visit www.tremfyahcp.com.

If you would like your product included in Product News, please email a press release to the Editorial Office at cutis@frontlinemedcom.com.

Avène A-OXitive

Pierre Fabre Dermo-Cosmetique introduces Avène A-OXitive Antioxidant Defense Serum and Avène A-OXitive Antioxidant Water-Cream to fight against oxidative stress. Stable forms of time-released vitamin E and vitamin C work synergistically to defend against environmental aggressors without irritation. Both products contain hyaluronic acid to visibly plump and firm the skin and soothing Avène thermal spring water to soften and restore the skin’s balance. To preserve stability, each formula comes in an airless pump bottle. For more information, visit www.aveneusa.com.

Orencia

Bristol-Myers Squibb Company announces US Food and Drug Administration approval of Orencia (abatacept) for the treatment of adults with active psoriatic arthritis. Orencia is available in both intravenous and subcutaneous injection formulations. It should not be administered concomitantly with tumor necrosis factor antagonists and is not recommended for use with other biologic rheumatoid arthritis therapy. Orencia also is indicated for the treatment of adult rheumatoid arthritis and juvenile idiopathic arthritis. For more information, visit www.orenciahcp.com.

Tremfya

Janssen Biotech, Inc, announces US Food and Drug Administration approval of Tremfya (guselkumab) for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Tremfya is a biologic therapy that selectively blocks only IL-23, a cytokine that plays a key role in plaque psoriasis. Tremfya is administered as a 100-mg subcutaneous injection every 8 weeks, following 2 starter doses at weeks 0 and 4. Clinical studies documented skin clearance at week 16 and up to week 48. For more information, visit www.tremfyahcp.com.

If you would like your product included in Product News, please email a press release to the Editorial Office at cutis@frontlinemedcom.com.

Avène A-OXitive

Pierre Fabre Dermo-Cosmetique introduces Avène A-OXitive Antioxidant Defense Serum and Avène A-OXitive Antioxidant Water-Cream to fight against oxidative stress. Stable forms of time-released vitamin E and vitamin C work synergistically to defend against environmental aggressors without irritation. Both products contain hyaluronic acid to visibly plump and firm the skin and soothing Avène thermal spring water to soften and restore the skin’s balance. To preserve stability, each formula comes in an airless pump bottle. For more information, visit www.aveneusa.com.

Orencia

Bristol-Myers Squibb Company announces US Food and Drug Administration approval of Orencia (abatacept) for the treatment of adults with active psoriatic arthritis. Orencia is available in both intravenous and subcutaneous injection formulations. It should not be administered concomitantly with tumor necrosis factor antagonists and is not recommended for use with other biologic rheumatoid arthritis therapy. Orencia also is indicated for the treatment of adult rheumatoid arthritis and juvenile idiopathic arthritis. For more information, visit www.orenciahcp.com.

Tremfya

Janssen Biotech, Inc, announces US Food and Drug Administration approval of Tremfya (guselkumab) for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Tremfya is a biologic therapy that selectively blocks only IL-23, a cytokine that plays a key role in plaque psoriasis. Tremfya is administered as a 100-mg subcutaneous injection every 8 weeks, following 2 starter doses at weeks 0 and 4. Clinical studies documented skin clearance at week 16 and up to week 48. For more information, visit www.tremfyahcp.com.

If you would like your product included in Product News, please email a press release to the Editorial Office at cutis@frontlinemedcom.com.

DIAGNOSE HERPES SIMPLEX VIRUS

According to the CDC, infections with HSV-2 affect more than 24 million Americans. Patients with HSV-2 strain are at increased risk for contracting and transmitting HIV. Pregnant women infected with HSV-2 are at risk of transmitting the virus to their babies, with increased risk for neurologic complications in the child. 

FOR MORE INFORMATION, VISIT: http://www.hologic.com/search/site/aptima%20hsv

PRECISELY TARGET TISSUE DURING LUMPECTOMY OR BIOPSY

Cianna Medical reported recent data showing that, when compared with wire localization, the SCOUT reduces breast surgery operating room (OR) delay times by 72.5%, resulted in an average 29- minute reduction in OR waiting time, and significantly improved workflow efficiency.

FOR MORE INFORMATION, VISIT: https://www.ciannamedical.com/savi-scout/

PLASMA HYSTEROSCOPIC RESECTION

During gynecologic procedures, the Olympus 8.5-mm hystero-resectoscope uses a combination of radio frequency, energy, and saline to create plasma, an electrically conductive gas cloud of vapor and charged particles. Due to its conductivity, plasma allows energy to cross into targeted tissue at lower energy levels than with more traditional approaches. This effect leads to lower operating temperatures and therefore less thermal spread.

FOR MORE INFORMATION, VISIT:  http://olympusmedical.com.sg

APP-BASED HANDHELD ULTRASOUND

High-resolution images can be saved, reviewed, and managed on the secure Clarius Cloud. Built with a durable magnesium shell, each device has an IPX7 immersion rating so it can be sterilized. Power is obtained from a rechargeable battery that will last for more than 45 minutes of scanning; 2 batteries come with each Clarius device.

FOR MORE INFORMATION, VISIT: https://www.clarius.me/

Share your thoughts! Send your Letter to the Editor to rbarbieri@frontlinemedcom.com. Please include your name and the city and state in which you practice.

DIAGNOSE HERPES SIMPLEX VIRUS

According to the CDC, infections with HSV-2 affect more than 24 million Americans. Patients with HSV-2 strain are at increased risk for contracting and transmitting HIV. Pregnant women infected with HSV-2 are at risk of transmitting the virus to their babies, with increased risk for neurologic complications in the child. 

FOR MORE INFORMATION, VISIT: http://www.hologic.com/search/site/aptima%20hsv

PRECISELY TARGET TISSUE DURING LUMPECTOMY OR BIOPSY

Cianna Medical reported recent data showing that, when compared with wire localization, the SCOUT reduces breast surgery operating room (OR) delay times by 72.5%, resulted in an average 29- minute reduction in OR waiting time, and significantly improved workflow efficiency.

FOR MORE INFORMATION, VISIT: https://www.ciannamedical.com/savi-scout/

PLASMA HYSTEROSCOPIC RESECTION

During gynecologic procedures, the Olympus 8.5-mm hystero-resectoscope uses a combination of radio frequency, energy, and saline to create plasma, an electrically conductive gas cloud of vapor and charged particles. Due to its conductivity, plasma allows energy to cross into targeted tissue at lower energy levels than with more traditional approaches. This effect leads to lower operating temperatures and therefore less thermal spread.

FOR MORE INFORMATION, VISIT:  http://olympusmedical.com.sg

APP-BASED HANDHELD ULTRASOUND

High-resolution images can be saved, reviewed, and managed on the secure Clarius Cloud. Built with a durable magnesium shell, each device has an IPX7 immersion rating so it can be sterilized. Power is obtained from a rechargeable battery that will last for more than 45 minutes of scanning; 2 batteries come with each Clarius device.

FOR MORE INFORMATION, VISIT: https://www.clarius.me/

Share your thoughts! Send your Letter to the Editor to rbarbieri@frontlinemedcom.com. Please include your name and the city and state in which you practice.

DIAGNOSE HERPES SIMPLEX VIRUS

According to the CDC, infections with HSV-2 affect more than 24 million Americans. Patients with HSV-2 strain are at increased risk for contracting and transmitting HIV. Pregnant women infected with HSV-2 are at risk of transmitting the virus to their babies, with increased risk for neurologic complications in the child. 

FOR MORE INFORMATION, VISIT: http://www.hologic.com/search/site/aptima%20hsv

PRECISELY TARGET TISSUE DURING LUMPECTOMY OR BIOPSY

Cianna Medical reported recent data showing that, when compared with wire localization, the SCOUT reduces breast surgery operating room (OR) delay times by 72.5%, resulted in an average 29- minute reduction in OR waiting time, and significantly improved workflow efficiency.

FOR MORE INFORMATION, VISIT: https://www.ciannamedical.com/savi-scout/

PLASMA HYSTEROSCOPIC RESECTION

During gynecologic procedures, the Olympus 8.5-mm hystero-resectoscope uses a combination of radio frequency, energy, and saline to create plasma, an electrically conductive gas cloud of vapor and charged particles. Due to its conductivity, plasma allows energy to cross into targeted tissue at lower energy levels than with more traditional approaches. This effect leads to lower operating temperatures and therefore less thermal spread.

FOR MORE INFORMATION, VISIT:  http://olympusmedical.com.sg

APP-BASED HANDHELD ULTRASOUND

High-resolution images can be saved, reviewed, and managed on the secure Clarius Cloud. Built with a durable magnesium shell, each device has an IPX7 immersion rating so it can be sterilized. Power is obtained from a rechargeable battery that will last for more than 45 minutes of scanning; 2 batteries come with each Clarius device.

FOR MORE INFORMATION, VISIT: https://www.clarius.me/

Share your thoughts! Send your Letter to the Editor to rbarbieri@frontlinemedcom.com. Please include your name and the city and state in which you practice.

Glytone Sunscreen Lotion Broad Spectrum SPF 40

Pierre Fabre Dermo-Cosmetique USA introduces Glytone Sunscreen Lotion Broad Spectrum SPF 40, a mineral-based formula for face and body with micronized zinc oxide, octinoxate, and octisalate. The lightweight formula is water resistant for up to 40 minutes and contains hyaluronic acid to nourish the skin and help boost natural moisture levels to visibly reduce the appearance of fine lines and wrinkles. For more information, visit www.glytone-usa.com.

proactivMD

The Proactiv Company launches the proactivMD Essentials System, a 3-step acne regimen that has been reformulated to include the topical retinoid adapalene. Step 1 is the Deep Cleansing Face Wash formulated to help clear dirt and debris from deep within the pores. Step 2 is the Balancing Toner, an alcohol-free formula that contains a light astringent to sweep away impurities leaving the skin feeling fresh and balanced. Step 3 consists of the Daily Oil Control Moisturizer (morning), which protects the skin and controls shine, and Adapalene Gel 0.1% (evening) to speed acne healing and prevent new acne from forming. For more information, visit www.proactiv.com.

If you would like your product included in Product News, please email a press release to the Editorial Office at cutis@frontlinemedcom.com.

Glytone Sunscreen Lotion Broad Spectrum SPF 40

Pierre Fabre Dermo-Cosmetique USA introduces Glytone Sunscreen Lotion Broad Spectrum SPF 40, a mineral-based formula for face and body with micronized zinc oxide, octinoxate, and octisalate. The lightweight formula is water resistant for up to 40 minutes and contains hyaluronic acid to nourish the skin and help boost natural moisture levels to visibly reduce the appearance of fine lines and wrinkles. For more information, visit www.glytone-usa.com.

proactivMD

The Proactiv Company launches the proactivMD Essentials System, a 3-step acne regimen that has been reformulated to include the topical retinoid adapalene. Step 1 is the Deep Cleansing Face Wash formulated to help clear dirt and debris from deep within the pores. Step 2 is the Balancing Toner, an alcohol-free formula that contains a light astringent to sweep away impurities leaving the skin feeling fresh and balanced. Step 3 consists of the Daily Oil Control Moisturizer (morning), which protects the skin and controls shine, and Adapalene Gel 0.1% (evening) to speed acne healing and prevent new acne from forming. For more information, visit www.proactiv.com.

If you would like your product included in Product News, please email a press release to the Editorial Office at cutis@frontlinemedcom.com.

Glytone Sunscreen Lotion Broad Spectrum SPF 40

Pierre Fabre Dermo-Cosmetique USA introduces Glytone Sunscreen Lotion Broad Spectrum SPF 40, a mineral-based formula for face and body with micronized zinc oxide, octinoxate, and octisalate. The lightweight formula is water resistant for up to 40 minutes and contains hyaluronic acid to nourish the skin and help boost natural moisture levels to visibly reduce the appearance of fine lines and wrinkles. For more information, visit www.glytone-usa.com.

proactivMD

The Proactiv Company launches the proactivMD Essentials System, a 3-step acne regimen that has been reformulated to include the topical retinoid adapalene. Step 1 is the Deep Cleansing Face Wash formulated to help clear dirt and debris from deep within the pores. Step 2 is the Balancing Toner, an alcohol-free formula that contains a light astringent to sweep away impurities leaving the skin feeling fresh and balanced. Step 3 consists of the Daily Oil Control Moisturizer (morning), which protects the skin and controls shine, and Adapalene Gel 0.1% (evening) to speed acne healing and prevent new acne from forming. For more information, visit www.proactiv.com.

If you would like your product included in Product News, please email a press release to the Editorial Office at cutis@frontlinemedcom.com.

NONESTROGEN PRODUCT FOR DYSPAREUNIA

FOR MORE INFORMATION, VISIT: http://www.amagpharma.com

ORAL MAINTENANCE TX FOR RECURRENT CANCER

FOR MORE INFORMATION, VISIT: http://www.zejula.com

MIGS STAPLING SYSTEM WITH REAL-TIME FEEDBACK

FOR MORE INFORMATION, VISIT: http://www.medtronic.com

BONE BUILDING AGENT

FOR MORE INFORMATION, VISIT: http://www.radiuspharm.com

PROTEOMIC BREAST CANCER ASSAY

FOR MORE INFORMATION, VISIT: http://www.provistadx.com

Share your thoughts! Send your Letter to the Editor to rbarbieri@frontlinemedcom.com. Please include your name and the city and state in which you practice.

NONESTROGEN PRODUCT FOR DYSPAREUNIA

FOR MORE INFORMATION, VISIT: http://www.amagpharma.com

ORAL MAINTENANCE TX FOR RECURRENT CANCER

FOR MORE INFORMATION, VISIT: http://www.zejula.com

MIGS STAPLING SYSTEM WITH REAL-TIME FEEDBACK

FOR MORE INFORMATION, VISIT: http://www.medtronic.com

BONE BUILDING AGENT

FOR MORE INFORMATION, VISIT: http://www.radiuspharm.com

PROTEOMIC BREAST CANCER ASSAY

FOR MORE INFORMATION, VISIT: http://www.provistadx.com

Share your thoughts! Send your Letter to the Editor to rbarbieri@frontlinemedcom.com. Please include your name and the city and state in which you practice.

NONESTROGEN PRODUCT FOR DYSPAREUNIA

FOR MORE INFORMATION, VISIT: http://www.amagpharma.com

ORAL MAINTENANCE TX FOR RECURRENT CANCER

FOR MORE INFORMATION, VISIT: http://www.zejula.com

MIGS STAPLING SYSTEM WITH REAL-TIME FEEDBACK

FOR MORE INFORMATION, VISIT: http://www.medtronic.com

BONE BUILDING AGENT

FOR MORE INFORMATION, VISIT: http://www.radiuspharm.com

PROTEOMIC BREAST CANCER ASSAY

FOR MORE INFORMATION, VISIT: http://www.provistadx.com

Share your thoughts! Send your Letter to the Editor to rbarbieri@frontlinemedcom.com. Please include your name and the city and state in which you practice.